Please assess the completion status of the following clinical trial:

Trial Title: ACZ885 for the Treatment of Abdominal Aortic Aneurysm

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Male and female subjects age ≥45 years of age~2. Infrarenal abdominal aortic aneurysm with maximum diameter: for men ≥40mm and ≤50mm; for women ≥38mm and ≤48mm.~3. On a stable medical regimen for at least 2 weeks prior to dosing, per investigator assessment.~4. Have an evaluable ultrasound image at screening for the quantitative determination of the AAA size, per imaging core lab assessment.~5. At screening, vital signs should be within the following ranges: (a) oral body temperature between 35.0-37.5°C; (b) systolic blood pressure, 90-170 mm Hg; (c) diastolic blood pressure, 50-100 mm Hg; (d) pulse rate, 40 - 100 bpm.~Key Exclusion Criteria:~1. Use of other investigational drugs at the time of enrollment, or within 5 half-lives of enrollment.~2. Known diabetes by medical history, an HbA1c of ≥6.5% at screening, or on an active diabetic medical regimen.~3. History of malignancy of any organ system other than localized basal cell carcinoma of the skin, treated or untreated, within the past 5 years.~4. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of contraception during dosing and 30-day follow up period of the study.~5. Donation or loss of 400 ml or more of blood within eight (8) weeks prior to initial dosing, or longer if required by local regulation.~6. Subjects on the following medications: (a) Chronic systemic steroid treatment or other systemic immunosuppression; (b) Any biologic drugs targeting the immune system, along with a history of any previous use of such drugs.~7. Presence of a non-healing wound or infection, including active urinary tract infections, or any recent process requiring significant tissue healing per investigator assessment.~8. Significant illness which has not resolved within four (4) weeks prior to initial dosing or with a life expectancy less than 2 years.~9. Any of the following concomitant hepatic or renal conditions or diseases: (a) Nephrotic syndrome, or eGFR less than 30 mL/min/1.73 m2 per CRCL formula; (b) Prior organ transplant requiring immunosuppressive therapy; (c) Known active or recurrent hepatic disorder.~10. Previous infra-renal aortic surgery~11. Planned major surgery~12. Known aortic dissection~13. Subjects with eligible AAA diameter, but with known slow growth (\<2mm/year) or known stable AAA size over the prior one year of surveillance per investigator assessment.~14. Subjects should exhibit no signs of clinically concerning unstable acceleration of AAA size or growth rate at the time of enrollment per investigator assessment.~15. Known or suspected inherited connective tissue disorders (e.g., Marfan or Vascular Ehlers Danlos syndrome).~16. Recently unstable clinically significant cardiac disease within 3 months of screening, including but not limited to, unstable angina, acute myocardial infarction, and congestive heart failure (NYHA class IV).~17. Uncontrolled or refractory hypertension per Investigator determination.~18. Live vaccinations within 3 months prior to randomization, or live vaccinations planned during the study.~19. History of untreated tuberculosis infection or evidence of active tuberculosis (TB) infection.~20. History of multiple and recurring allergies or allergy to the investigational compound/compound class being used in this study.~21. History of immunodeficiency diseases, including a positive HIV (ELISA and Western blot) test result.~22. A positive Hepatitis B surface antigen or Hepatitis C test result whether at screening or historically.~23. For USA sites utilizing CT angiograms, subjects with a history of a previous reaction to contrast agent, a known sensitivity to iodine and known allergies (e.g, shellfish allergy), or other hypersensitivities to contrast agents.~24. Underlying immune disorders, autoimmunity or immunodeficiency.~25. History of drug or alcohol abuse within the 12 months prior to dosing.

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ACZ885 (Type: EXPERIMENTAL): Participants received ACZ885 150 mg subcutaneously (s.c.) once per month for 12 months.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received matching placebo to ACZ885 s.c. once per month for 12 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy